Charles E. Leonard

Charles E. Leonard


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2009 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
SHSean Hennessy
Sean Hennessy
CLCharles E. Leonard
Charles E. Leonard
CFCristin P. Freeman
Cristin P. Freeman
RDRajat Deo
Rajat Deo
CNCraig Newcomb
Craig Newcomb
WBWarren B. Bilker
Warren B. Bilker

28 July 2011 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
CLCharles E. Leonard
Charles E. Leonard
WBWarren B. Bilker
Warren B. Bilker
CNCraig Newcomb
Craig Newcomb
SKStephen E. Kimmel
Stephen E. Kimmel
SHSean Hennessy
Sean Hennessy

15 July 2020 in Journal of Bone and Joint Surgery
Verified
Journal Article
Closed access
MGMichael D. George
Michael D. George
JBJoshua F. Baker
Joshua F. Baker
CLCharles E. Leonard
Charles E. Leonard
SMSamir Mehta
Samir Mehta
TMTodd A. Miano
Todd A. Miano
SHSean Hennessy
Sean Hennessy
Background: Cyclooxygenase-2 (COX-2) has been found to be important for fracture-healing in animal models, raising concerns about use of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors after fractures. We evaluated associations of NSAIDs, COX-2 inhibitors, and opioids with nonunion after long-bone fracture. Methods: Using private health insurance claims data from Optum’s de-identified Clinformatics Data Mart database from January 1, 2000, to September 30, 2015, we identified adults with a single long-bone fracture or commonly paired long-bone fractures who had 1 year of available follow-up data. Using multivariable logistic regression models, we examined associations between NSAID, COX-2-inhibitor, or opioid prescription fills after the fracture and the risk of nonunion within 1 year, defined as a nonunion diagnosis with a procedure to treat the nonunion. Results: A nonunion diagnosis with a procedure to treat the nonunion was identified after 2,996 (0.9%) of the 339,864 fracture episodes, with rates varying by fracture site. The risk of that outcome was greater in patients who had filled COX-2-inhibitor prescriptions (adjusted odds ratio = 1.84 [95% confidence interval = 1.38 to 2.46]) or opioid prescriptions (1.69 [1.53 to 1.86]), but not in patients who had filled nonselective-NSAID prescriptions (1.07 [0.93 to 1.23]) after the fracture. Results were similar when the outcome definition was changed to just a nonunion diagnosis. Conclusions: COX-2 inhibitors, but not nonselective NSAIDs, were associated with a greater risk of nonunion after fracture. Opioids were also associated with nonunion risk, although patients filling prescriptions for opioids may have had more severe fractures. Level of Evidence: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.

9 August 2012 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
CLCharles E. Leonard
Charles E. Leonard
CFCristin P. Freeman
Cristin P. Freeman
CNCraig W. Newcomb
Craig W. Newcomb
PRPeter P. Reese
Peter P. Reese
MHMaximilian Herlim
Maximilian Herlim
BSBrian L. Strom
Brian L. Strom

1 January 2022 in Annals of Internal Medicine
Verified
Journal Article
Closed access
GDGhadeer K. Dawwas
Ghadeer K. Dawwas
CLCharles E. Leonard
Charles E. Leonard
JLJames D. Lewis
James D. Lewis
ACAdam Cuker
Adam Cuker
Few head-to-head comparisons of apixaban versus rivaroxaban for treating venous thromboembolism (VTE) have been published. This population-based, matched cohort study assessed the effectiveness and... Visual Recurrent VTE and Bleeding With Apixaban Versus Rivaroxaban. Few head-to-head comparisons of apixaban versus rivaroxaban for treating venous thromboembolism (VTE) have been publishe... Background: Apixaban and rivaroxaban are replacing vitamin K antagonists for the treatment of venous thromboembolism (VTE) in adults; however, head-to-head comparisons remain limited. Objective: To...

6 November 2017 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
CLCharles E. Leonard
Charles E. Leonard
XHXu Han
Xu Han
CBColleen M. Brensinger
Colleen M. Brensinger
WBWarren B. Bilker
Warren B. Bilker
SCSerena Cardillo
Serena Cardillo
SHSean Hennessy
Sean Hennessy